GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC.
Honghong FanYuxin ShiHuiyu WangYuting LiJie MeiJuanying XuChaoying LiuPublished in: International journal of general medicine (2023)
In summary, our current research suggests that GBP5 expression is a potential biomarker for predicting the outcome of NSCLC patients treated with ICIs. More research with large-scale samples is needed to determine their value as biomarkers of ICIs benefit.